Cancer diagnostics company Cernostics has raised $2.5 million in a Series A1 financing round, which will help the startup intensify its clinical and market development studies for its TissueCypher product.
The funding round was led by by San Francisco-based Illumina Ventures and the Cernostics product is designed to predict the risk of esophageal cancer in patients with Barrett’s esophagus. The disease affects more than three million Americans and its caused by chronic exposure of the esophageal lining to stomach acid.
In 2016, UPMC Enterprises, the commercialization arm of health-care giant UPMC, was the lead investor in a $5 million round of funding for Cernostics, which has offices in Harmar and Bethlehem, Pa.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.